文献速递前列腺癌

循环肿瘤细胞上的Prostein表达作为转移性去势抵抗性前列腺癌的预后标志物

Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-12-06

研究纳入87例转移性去势抵抗性前列腺癌(mCRPC)患者基线样本,用CellSearch系统计数循环肿瘤细胞(CTC)并以免疫染色识别Prostein阳性CTC。基线Prostein阳性患者31例,其PSA缓解率(0%,0/31)显著低于Prostein阴性患者(19.6%,11/56)(p=0.007),且PSA-PFS、影像学PFS和OS均显著更短。作者认为Prostein表达可能作为新型预后标志物,但需未来大规模前瞻性研究验证。

要点

  • 基线Prostein阳性CTC见于31/87例mCRPC患者,首次随访时见于16/51例样本。
  • 基线Prostein阳性患者PSA缓解率为0%(0/31),低于Prostein阴性患者的19.6%(11/56)(p=0.007)。
  • 基线Prostein阳性与更短PSA-PFS(p<0.001)、影像学PFS(p<0.001)和OS(p=0.018)相关。

核心结论

  • 本研究首次提供证据支持CTC上的Prostein表达可能作为mCRPC患者的新型预后标志物,但需未来大规模前瞻性研究验证。

研究设计与样本

  • 研究纳入mCRPC患者,用CellSearch系统计数CTC,并通过免疫染色结果识别Prostein阳性CTC。
  • 基线样本87例,首次随访样本51例;基线Prostein阳性31例、阴性56例。

主要发现

  • 基线Prostein阳性患者31/87例,首次随访样本中Prostein阳性16/51例。
  • 基线Prostein阳性患者PSA缓解率为0%(0/31),Prostein阴性患者为19.6%(11/56),差异有统计学意义(p=0.007)。
  • 基线Prostein阳性患者较Prostein阴性患者PSA-PFS显著更短(p<0.001)、影像学PFS显著更短(p<0.001)、OS显著更短(p=0.018)。
  • 多因素分析中,Prostein表达与PSA-PFS的关联保持显著(p=0.028)。
  • 分析首次随访时Prostein表达及基线至随访的Prostein表达转换,不仅证实与PSA-PFS的关联,也显示与OS的预后意义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需未来大规模前瞻性研究验证本研究发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Identification of emerging molecular biomarkers on circulating tumor cells (CTCs) represents an attractive feature of liquid biopsy that facilitates precision and tailored medicine in the management of metastatic castration-resistant prostate cancer (mCRPC). Prostein is an androgen-regulated transmembrane protein with high prostate specificity. Prostein-positive circulating tumor cell (CTC) was recently suggested to have diagnostic potential; however, no study has been conducted to evaluate its prognostic value in mCRPC. METHODS: CTCs from mCRPC patients were enumerated using the CellSearch System. Prostein-positive CTCs were identified by immunostaining results. The relationships between prostein expression on CTCs and PSA response rate, PSA progression-free survival (PSA-PFS), radiographic progression-free survival (PFS), and overall survival (OS) were tested by Fisher's exact test or evaluated using Kaplan-Meier and multivariate Cox analyses. RESULTS: Prostein-positive CTCs were identified in 31 of 87 baseline samples from mCRPC patients and 16 of 51 samples collected at the first follow-up visit. PSA response rates were significantly lower in baseline prostein-positive patients (0%, 0/31) than in prostein-negative patients (19.6%, 11/56) (p = 0.007). The 31 prostein-positive patients had significantly shorter PSA-PFS (p < 0.001), radiographic PFS (p < 0.001), and OS (p = 0.018), compared to the 56 prostein-negative patients at baseline. The association with PSA-PFS maintained its significance (p = 0.028) in multivariate analyses. Analyzing prostein expression at the first follow-up as well as the conversion of prostein expression from baseline to follow-up samples not only confirmed the association with PSA-PFS, but also demonstrated prognostic significance with OS. CONCLUSION: Our study provides the first evidence to support the potential of prostein expression on CTCs to serve as a novel prognostic marker in mCRPC patients. Future large-scale prospective studies are needed to validate our findings.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Zhang Z, Luo R, Kelly WK, et al. Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2023. PMID: 38057610. doi:10.1038/s41391-023-00762-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。